Elsevier Congratulates Royal Australian Chemical Institute's 2010/11 Athel Beckwith Lectureship Winner

Dr. Scott Stewart, From the University of Western Australia Wins Reaxys(R) Sponsored Lectureship as an Outstanding Recently Appointed Organic Chemist

NEUCHATEL, Switzerland, August 5, 2010 - Elsevier Properties SA is pleased to congratulate Dr. Scott
Stewart on his winning the Royal Australian Chemical Institute's (RACI)
2010/11 Athel Beckwith Lectureship, sponsored by Reaxys.

The award is open to all RACI members who have been appointed to their
first academic or industrial position within the past five years. As the
award winner, Dr. Stewart will be given the opportunity to present a lecture
in at least six Australian state capitals and/or major regional centers
during the year of the lectureship. The Organic Division of RACI established
the annual lectureship to provide funding for outstanding early career
organic chemists to travel around Australia and present the results of their
research work.

Dr. Stewart, from the University of Western Australia,
completed a PhD at the Research School of Chemistry (ANU) on the
enantioselective synthesis of two new anti-cancer agents Taxol and
Phomopsidin. His research interests include the synthesis of biologically
active natural products using palladium catalysed cross coupling reactions;
domino transformations in synthetic chemistry; medicinal chemistry for the
treatment of cancer and immune diseases; and intramolecular Heck reactions
using new nickel and palladium catalysts.

David Evans PhD, Scientific Affairs Director at Elsevier
Properties SA said, "This lectureship provides a unique opportunity for
chemists in the early stages of their careers and we would like to
congratulate Dr. Stewart for his achievement in winning this award. We are
pleased that this award grants scientists the recognition they deserve."

Reaxys is a unique web-based chemistry database combining
reaction and substance data in organic, organometallic, inorganic and
physical chemistry with synthesis planning. Reaxys allows researchers to get
the information they need in a single overview, from source publications
carefully selected for their importance and relevance to research chemists.

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed
Elsevier for the management of intellectual property. Elsevier Properties SA
owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including
Reaxys(R), PharmaPendium(TM), SciVal(R) and The Lancet(R) are owned and
protected by Elsevier Properties SA and used under license. For additional
information see www.reedelsevier.com .

About Elsevier

Elsevier is a world-leading publisher of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com),
Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and
Nursing Consult (www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(www.scival.com) and MEDai's Pinpoint Review (www.medai.com),
which help research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier
(www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact:

    Tom Reller
    Elsevier
    +1-215-239-3508
    T.Reller@elsevier.com

Media Contact: Tom Reller, Elsevier, +1-215-239-3508, T.Reller at elsevier.com .